RxSight, Inc. Company Profile

Background

RxSight, Inc. is a commercial-stage medical technology company specializing in the development, manufacturing, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery. Founded in 1997 and headquartered in Aliso Viejo, California, the company aims to revolutionize the premium cataract surgery experience by enabling surgeons to customize and enhance visual outcomes for patients post-surgery.

Key Strategic Focus

RxSight's strategic focus centers on providing high-quality, customized vision solutions following cataract surgery. The company's primary objectives include:

• Core Objectives: Enhancing visual acuity outcomes through adjustable intraocular lenses, thereby improving patient satisfaction and surgical precision.

• Areas of Specialization: Development and commercialization of the Light Adjustable Lens (LAL) system, which allows for post-operative adjustments to optimize vision.

• Key Technologies Utilized: Photosensitive materials in LALs that change shape in response to specific ultraviolet light patterns, enabling precise vision correction.

• Primary Markets Targeted: Cataract surgery patients seeking personalized visual outcomes, with a focus on the U.S. market and expanding international presence.

Financials and Funding

RxSight went public on July 30, 2021, with an initial public offering (IPO) of 7,350,000 shares at $16.00 per share, raising approximately $117.6 million in gross proceeds. In May 2024, the company conducted a public offering of 1,785,714 shares at $56.00 per share, generating about $100.0 million in gross proceeds. As of April 11, 2026, RxSight's stock (NASDAQ: RXST) is trading at $6.83 per share, with a market capitalization of approximately $367.8 million.

Pipeline Development

RxSight's product pipeline is focused on the advancement of its Light Adjustable Lens (LAL) system:

• Key Pipeline Candidates: LAL and LAL+ lenses designed for post-operative vision customization.

• Stages of Development: The LAL system has been commercialized, with ongoing enhancements to improve lens performance and patient outcomes.

• Target Conditions: Cataract-induced vision impairment, with a focus on providing adjustable solutions for optimal post-surgical vision.

• Anticipated Milestones: Expansion of the installed base of Light Delivery Devices (LDDs) and increased adoption of LAL procedures among ophthalmic surgeons.

Technological Platform and Innovation

RxSight's technological platform is distinguished by:

• Proprietary Technologies: The Light Adjustable Lens (LAL) system, which utilizes photosensitive materials to allow for post-operative adjustments to lens shape, enabling precise vision correction.

• Significant Scientific Methods: Use of ultraviolet light patterns to modify lens curvature, facilitating individualized visual outcomes.

• AI-Driven Capabilities: While specific AI applications are not detailed, the company's focus on precision and customization suggests potential integration of advanced technologies in future developments.

Leadership Team

The leadership team at RxSight includes:

• Ron Kurtz, M.D.: President and Chief Executive Officer since 2016, with a background in co-founding and leading LenSx Lasers, Inc. and IntraLase Corp.

• Eric Weinberg: Chief Business Development Officer, previously Chief Commercial Officer, with experience in co-founding LenSx Lasers, Inc. and roles at Alcon LenSx, Inc.

• Ilya Goldshleger, Ph.D.: Chief Operating Officer, responsible for engineering and development of the LAL system, with prior experience at Alcon LenSx, Inc.

• Mark Wilterding: Chief Financial Officer since January 2026, bringing over 25 years of financial leadership experience from Edwards Lifesciences and Medtronic.

• Scott Gaines: Chief Customer Officer, focusing on commercial operations and business processes, with a background in Alcon LenSx (Novartis) and IntraLase Corp.

• Maureen O'Connell: Executive Vice President of Clinical & Regulatory Affairs, with over 30 years in medical device regulatory affairs and clinical study management.

• Patrick Cullen: Executive Vice President of Quality & Infrastructure Operations, with experience in quality management at Alcon (Novartis) and Saint Jude Medical.

• Adam Dashe: Executive Vice President of International, leading global market expansion, with prior roles at Edwards Lifesciences.

Market Insights and Competitor Profile

The ophthalmic medical device market, particularly in the area of intraocular lenses for cataract surgery, is characterized by:

• Market Size and Growth Potential: A substantial and growing market driven by an aging global population and increasing prevalence of cataract-related vision impairment.

• Industry Trends: A shift towards personalized and adjustable vision solutions, with technological advancements enabling more precise and customizable outcomes.

Key competitors in the intraocular lens market include:

• Alcon: A global leader in eye care, offering a range of intraocular lenses and surgical equipment.

• Bausch + Lomb: Provides a comprehensive portfolio of eye health products, including intraocular lenses and surgical instruments.

• Johnson & Johnson Vision: Offers a diverse range of ophthalmic products, including intraocular lenses and surgical tools.

• ZEISS: Known for precision optics, ZEISS offers intraocular lenses and surgical equipment.

• HOYA: Provides a variety of intraocular lenses and related surgical products.

These competitors have established market presence and extensive product portfolios, posing challenges to RxSight's market share.

Strategic Collaborations and Partnerships

RxSight has engaged in strategic collaborations to enhance its market position, including:

• Regulatory Approvals: Securing FDA approval for its Light Adjustable Lens system, facilitating market entry and expansion.

• Clinical Studies: Conducting studies to demonstrate the efficacy and safety of its products, thereby building credibility and trust among healthcare professionals.

Operational Insights

RxSight's operational strategy focuses on:

• Product Innovation: Continuously enhancing the Light Adjustable Lens system to meet evolving patient and surgeon needs.

• Market Expansion: Increasing the installed base of Light Delivery Devices and expanding into international markets to drive growth.

• Customer Engagement: Strengthening relationships with ophthalmic surgeons through education and support to promote adoption of its technologies.

Strategic Opportunities and Future Directions

RxSight's strategic roadmap includes:

• Product Development: Advancing the capabilities of the Light Adjustable Lens system to offer enhanced visual outcomes.

• Market Penetration: Expanding its presence in existing markets and entering new geographical regions to increase market share.

• Partnerships: Forming alliances with healthcare providers and research institutions to foster innovation and broaden distribution channels.

Contact Information

• Website: rxsight.com

• Social Media: LinkedIn